DISCOUNT-OPTIONSSCHEIN - AMGEN | Real-time BOERSE MUENCHEN 10:45:42 28/05/2024 BST | ||
| 0.71 EUR | -2.74% |
|
| Current month | +108.57% | ||
| 1 month | +135.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 0.71 | -2.74% |
| 27/05/24 | 0.73 | +5.80% |
| 24/05/24 | 0.69 | -1.43% |
| 23/05/24 | 0.7 | -14.63% |
| 22/05/24 | 0.82 | -8.89% |
Real-time BOERSE MUENCHEN
Last update May 28, 2024 at 10:45 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC9YKQ |
| ISIN | DE000HC9YKQ4 |
| Date issued | 17/10/2023 |
| Strike | 320 $ |
| Maturity | 18/09/2024 (114 Days) |
| Parity | 10 : 1 |
| Emission price | 0.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.22 € |
|---|---|
| Lowest since issue | 0.27 € |
| Spread | 0.07 € |
| Spread % | 9.86% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
- Stock Market
- Certificates
- Certificat
